To observe the oncogenic role of EGFR signaling in regulating IPO13 expression, we studied the effect of Osimertinib, a third generation of EGFR-TKI29 on IPO13 abundances in NSCLC cell lines. This evidence concerns the gene IPO13 and non-small cell lung carcinoma.